Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

British Journal of Clinical Pharmacology

Volumn 78, Issue 1, 2014, Pages 106-117

  Feng, Yan ^a   Masson, Eric ^a   Dai, David ^a,b   Parker, Susan M ^a   Berman, David ^a   Roy, Amit ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

cytotoxic T lymphocyte antigen 4; dose response relationship; drug effects; immunotherapy; monoclonal antibody

Indexed keywords

BUDESONIDE; IPILIMUMAB; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER STAGING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HALF LIFE TIME; HUMAN; IMMUNOGENICITY; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIMIT OF QUANTITATION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MILD HEPATIC IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 84902955889     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12323     Document Type: Article

References (35)

1. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L,. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95-106.
2. Fong L, Small EJ,. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275-5283.
3. Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R,. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37: 533-546.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
6. ClinicalTrial.gov. Phase 3 trial in subjects with metastatic melanoma comparing 3-mg/kg ipilimumab versus 10-mg/kg ipilimumab. Available at http://clinicaltrials.gov/show/NCT01515189 (last accessed 19 June 2013).
7. US Food and Drug Administration. Yervoy. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Label-ApprovalHistory#labelinfo (last accessed 13 June 2013).
8. European Medicines Agency. Yervoy. Available at http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/002213/human-med-001465. jsp&mid=WC0b01ac058001d124 (last accessed 13 June 2013).
9. Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber J,. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013; 19: 3977-3986.
10. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron L, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ,. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598.
11. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD,. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1717.
12. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C,. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
13. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gõmez H, Bastholt L, Chasalow SD, Berman D,. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9: 204-219.
14. WinPOPT: home. [online]. Available at http://www.winpopt.com/index.htm (last accessed 13 June 2013).
15. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E,. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26: 5950-5956.
16. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH,. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet 2012; 51: 573-590.
17. Montgomery DC, Peck EA, Vining GG,. Introduction to Linear Regression Analysis, 4th edn. New York: Wiley-Interscience, 2006.
18. Gastonguay M,. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. PAGE Conference, June 2011, Athens, Greece. Available at http://www.page-meeting.org/?abstract=2229 (last accessed 13 June 2013).
19. Harrell FE, Jr,. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer, 2010.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470.
21. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ,. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2010; 28: 4507-4512.
22. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-532.
23. Gibiansky L, Gibiansky E, Kakkar T, Ma P,. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 2008; 35: 573-591.
24. Mould DR, Green B,. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010; 24: 23-39.
25. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH,. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 493-507.
26. FDA Guidance for industry: population pharmacokinetics. 1999. Available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ WomensHealthResearch/UCM133184.pdf (last accessed 20 June 2013).
27. Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, Zhang Y, Joshi A, Dresser MJ,. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 2012; 51: 119-135.
28. Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ,. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010; 10: 9-14.
29. Newsome BW, Ernstoff MS,. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol 2008; 66: 6-19.
30. Menon-Andersen D, Yu B, Madabushi R, Bhattaram V, Hao W, Uppoor RS, Mehta M, Lesko L, Temple R, Stockbridge N, Laughren T, Gobburu JV,. Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label. Clin Pharmacol Ther 2011; 90: 471-474.
31. Rawa P, Gastonguay MR, Tensfeldt TG, Faessel TM,. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol 2009; 68: 669-681.
32. Riggs MM, Bergsma TT, Rogers JA, Gastonguay MR, Subramanian GM, Chen C, Devalaraja M, Corey AE, Sun H, Yu J, Stein DS,. Population pharmacokinetics and exposure-response of albinterferon alfa-2B. J Clin Pharmacol 2012; 52: 475-486.
33. Xu XS, Smit JW, Lin R, Stuyckens K, Terlinden R, Nandy P,. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet 2010; 49: 671-682.
34. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F,. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.
35. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG,. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216